Rett syndrome
Rett Syndrome Patient Dies in Neurogene Phase I/II Trial After High Dose of Gene Therapy
The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.
Neurogene Halts Testing High-Dose Rett Syndrome Gene Therapy After Adverse Event
Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.
Neurogene Dropping Batten Disease Gene Therapy; Discloses Adverse Event in Rett Syndrome Trial
Following these updates, the company's stock price fell by 31 percent, from $70.04 Monday morning when the Nasdaq opened to $48.28 on Tuesday morning.
Neurogene Announces $200M PIPE Financing
The company will use the funds to enroll a registrational trial for its investigational gene therapy NGN-401 for Rett syndrome.
In Brief This Week: German Cancer Aid, Labcorp, Neurogene, SCG Cell Therapy
News items for the week of Aug. 5, 2024.